At the time of writing, Nurix Therapeutics Inc [NRIX] stock is trading at $17.06, up 3.58%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NRIX shares have lost -1.67% over the last week, with a monthly amount drifted -13.88%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nurix Therapeutics Inc [NASDAQ: NRIX] stock has seen the most recent analyst activity on December 10, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $35. Previously, BMO Capital Markets started tracking the stock with Outperform rating on December 06, 2024, and set its price target to $35. On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $35 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $41 on October 11, 2024. Truist started tracking with a Buy rating for this stock on July 31, 2024, and assigned it a price target of $36.
For the past year, the stock price of Nurix Therapeutics Inc fluctuated between $10.16 and $29.56. Currently, Wall Street analysts expect the stock to reach $31.67 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $17.06 at the most recent close of the market. An investor can expect a potential return of 85.64% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
According to Nurix Therapeutics Inc [NASDAQ:NRIX], the company’s sales were 54.55M for trailing twelve months, which represents an -12.37% plunge. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -3.91%, Pretax Profit Margin comes in at -3.54%, and Net Profit Margin reading is -3.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.54 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.60 points at the first support level, and at 16.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.36, and for the 2nd resistance point, it is at 17.67.
Ratios To Look Out For
It is important to note that Nurix Therapeutics Inc [NASDAQ:NRIX] has a current ratio of 6.46. Further, the Quick Ratio stands at 6.46, while the Cash Ratio is 1.15. Considering the valuation of this stock, the price to sales ratio is 23.73, the price to book ratio is 2.46.
Transactions by insiders
Recent insider trading involved Ring Christine, Chief Legal Officer, that happened on Jan 31 ’25 when 5760.0 shares were sold. Officer, CHRISTINE RING completed a deal on Jan 31 ’25 to buy 5760.0 shares. Meanwhile, Chief Legal Officer Ring Christine sold 3220.0 shares on Jan 30 ’25.
